{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:48:00Z","timestamp":1787003280524,"version":"build-2736575974"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T00:00:00Z","timestamp":1596067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T00:00:00Z","timestamp":1596067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1038\/s41584-020-0474-5","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T09:05:55Z","timestamp":1596099955000},"page":"581-589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":208,"title":["Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4514-2382","authenticated-orcid":false,"given":"Joan T.","family":"Merrill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doruk","family":"Erkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald","family":"Winakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,30]]},"reference":[{"key":"474_CR1","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"W Guan","year":"2020","unstructured":"Guan, W. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708\u20131720 (2020).","journal-title":"N. Engl. J. Med."},{"key":"474_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41392-020-0148-4","volume":"5","author":"L Tan","year":"2020","unstructured":"Tan, L. et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct. Target. Ther. 5, 33 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"474_CR3","first-page":"3404","volume":"24","author":"R Zheng","year":"2020","unstructured":"Zheng, R. et al. Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur. Rev. Med. Pharmacol. Sci. 24, 3404\u20133410 (2020).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"474_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-020-02105-8","author":"S Yin","year":"2020","unstructured":"Yin, S., Huang, M., Li, D. & Tang, N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J. Thromb. Thrombolysis. https:\/\/doi.org\/10.1007\/s11239-020-02105-8 (2020).","journal-title":"J. Thromb. Thrombolysis."},{"key":"474_CR5","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054\u20131062 (2020).","journal-title":"Lancet"},{"key":"474_CR6","doi-asserted-by":"publisher","first-page":"e437","DOI":"10.1016\/S2665-9913(20)30121-1","volume":"2","author":"D McGonagle","year":"2020","unstructured":"McGonagle, D., O\u2019Donnell, J. S., Sharif, K., Emery, P. & Bridgewood, C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2, e437\u2013e445 (2020).","journal-title":"Lancet Rheumatol."},{"key":"474_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev.iy.13.040195.000333","volume":"13","author":"FV Chisari","year":"1995","unstructured":"Chisari, F. V. & Ferrari, C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13, 29\u201360 (1995).","journal-title":"Annu. Rev. Immunol."},{"key":"474_CR8","first-page":"365","volume":"390","author":"A Ascherio","year":"2015","unstructured":"Ascherio, A. & Munger, K. L. EBV and autoimmunity. Curr. Top. Microbiol. Immunol. 390, 365\u2013385 (2015).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"474_CR9","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.3389\/fimmu.2018.02147","volume":"9","author":"GL Lin","year":"2018","unstructured":"Lin, G. L., McGinley, J. P., Drysdale, S. B. & Pollard, A. J. Epidemiology and immune pathogenesis of viral sepsis. Front. Immunol. 9, 2147 (2018).","journal-title":"Front. Immunol."},{"key":"474_CR10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1126\/science.aao4555","volume":"360","author":"GS Ling","year":"2018","unstructured":"Ling, G. S. et al. C1q restrains autoimmunity and viral infection by regulating CD8+ T-cell metabolism. Science 360, 558\u2013563 (2018).","journal-title":"Science"},{"key":"474_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/imm.12349","volume":"143","author":"Y Zhou","year":"2014","unstructured":"Zhou, Y., Zhang, Y., Moorman, J. P., Yao, Z. Q. & Jia, Z. S. Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis. Immunology 143, 319\u2013330 (2014).","journal-title":"Immunology"},{"key":"474_CR12","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00178-20","volume":"94","author":"A Volk","year":"2020","unstructured":"Volk, A. et al. Coronavirus endoribonuclease and deubiquitinating interferon antagonists differentially modulate the host response during replication in macrophages. J. Virol. 94, e00178-20 (2020).","journal-title":"J. Virol."},{"key":"474_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/BOR.0b013e3283535801","volume":"24","author":"JA James","year":"2012","unstructured":"James, J. A. & Robertson, J. M. Lupus and Epstein-Barr. Curr. Opin. Rheumatol. 24, 383\u2013388 (2012).","journal-title":"Curr. Opin. Rheumatol."},{"key":"474_CR14","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.4049\/jimmunol.172.2.1287","volume":"172","author":"I Kang","year":"2004","unstructured":"Kang, I. et al. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J. Immunol. 172, 1287\u20131294 (2004).","journal-title":"J. Immunol."},{"key":"474_CR15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41422-020-0327-4","volume":"30","author":"W Cao","year":"2020","unstructured":"Cao, W. & Li, T. COVID-19: towards understanding of pathogenesis. Cell Res. 30, 367\u2013369 (2020).","journal-title":"Cell Res."},{"key":"474_CR16","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1136\/annrheumdis-2019-215361","volume":"78","author":"NR Jog","year":"2019","unstructured":"Jog, N. R. et al. Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals. Ann. Rheum. Dis. 78, 1235\u20131241 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"474_CR17","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/1529-0131(200105)44:5<1122::AID-ANR193>3.0.CO;2-D","volume":"44","author":"JA James","year":"2001","unstructured":"James, J. A. et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum. 44, 1122\u20131126 (2001).","journal-title":"Arthritis Rheum."},{"key":"474_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/978-1-0716-0211-9_15","volume":"2099","author":"R Channappanavar","year":"2020","unstructured":"Channappanavar, R. & Perlman, S. Evaluation of activation and inflammatory activity of myeloid cells during pathogenic human coronavirus infection. Methods Mol. Biol. 2099, 195\u2013204 (2020).","journal-title":"Methods Mol. Biol."},{"key":"474_CR19","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/S2468-1253(20)30118-7","volume":"5","author":"Y Wan","year":"2020","unstructured":"Wan, Y. et al. Enteric involvement in hospitalised patients with COVID-19 outside Wuhan. Lancet Gastroenterol. Hepatol. 5, 534\u2013535 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"474_CR20","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1097\/CM9.0000000000000744","volume":"133","author":"L Liu","year":"2020","unstructured":"Liu, L. et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin. Med. J. 133, 1025\u20131031 (2020).","journal-title":"Chin. Med. J."},{"key":"474_CR21","doi-asserted-by":"publisher","first-page":"200463","DOI":"10.1148\/radiol.2020200463","volume":"295","author":"A Berhnheim","year":"2020","unstructured":"Berhnheim, A. et al. Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiology 295, 200463 (2020).","journal-title":"Radiology"},{"key":"474_CR22","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1164\/rccm.202003-0817LE","volume":"201","author":"L Gattinoni","year":"2020","unstructured":"Gattinoni, L. et al. COVID-19 does not lead to a \u201ctypical\u201d acute respiratory distress syndrome. Am. J. Resp. Crit. Care Med. 201, 1299\u20131300 (2020).","journal-title":"Am. J. Resp. Crit. Care Med."},{"key":"474_CR23","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1097\/CM9.0000000000000775","volume":"133","author":"W Liu","year":"2020","unstructured":"Liu, W. et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin. Med. J. 133, 1032\u20131038 (2020).","journal-title":"Chin. Med. J."},{"key":"474_CR24","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41577-020-0308-3","volume":"20","author":"X Cao","year":"2020","unstructured":"Cao, X. COVID-19: immunopathology and its implications for therapy. Nat. Rev. Immunol. 20, 269\u2013270 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"474_CR25","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.4269\/ajtmh.15-0920","volume":"94","author":"KH Herbinger","year":"2015","unstructured":"Herbinger, K. H. et al. Lymphocytosis and lymphopenia induced by imported infectious diseases: a controlled cross-sectional study of 17,229 diseased German travelers returning from the tropics and subtropics. Am. J. Trop. Med. Hyg. 94, 1385\u20131391 (2015).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"474_CR26","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1001\/jamacardio.2020.0950","volume":"5","author":"S Shi","year":"2020","unstructured":"Shi, S. et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 5, 802\u2013810 (2020).","journal-title":"JAMA Cardiol"},{"key":"474_CR27","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1016\/S2352-3026(20)30109-5","volume":"7","author":"T Wang","year":"2020","unstructured":"Wang, T. et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol. 7, e362\u2013e363 (2020).","journal-title":"Lancet Haematol"},{"key":"474_CR28","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1378\/chest.111.3.661","volume":"111","author":"PE Marik","year":"1997","unstructured":"Marik, P. E., Andrews, L. & Maini, B. The incidence of deep venous thrombosis in ICU patients. Chest 111, 661\u2013664 (1997).","journal-title":"Chest"},{"key":"474_CR29","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/jth.14768","volume":"18","author":"N Tang","year":"2020","unstructured":"Tang, N., Li, D., Wan, X. & Sun, Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 18, 844\u2013847 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"474_CR30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2009787","volume":"382","author":"TJ Oxley","year":"2020","unstructured":"Oxley, T. J. et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. N. Engl. J. Med. 382, e60 (2020).","journal-title":"N. Engl. J. Med."},{"key":"474_CR31","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.thromres.2020.04.041","volume":"191","author":"FA Klok","year":"2020","unstructured":"Klok, F. A. et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb. Res. 191, 148\u2013150 (2020).","journal-title":"Thromb. Res."},{"key":"474_CR32","doi-asserted-by":"publisher","first-page":"137799","DOI":"10.1172\/jci.insight.137799","volume":"23","author":"F Wang","year":"2020","unstructured":"Wang, F., Hou, H., Luo, Y., Tang, G. & Wu, S. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight 23, 137799 (2020).","journal-title":"JCI Insight"},{"key":"474_CR33","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00011-020-01342-0","volume":"69","author":"J Yuan","year":"2020","unstructured":"Yuan, J. et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflamm. Res. 69, 599\u2013606 (2020).","journal-title":"Inflamm. Res."},{"key":"474_CR34","unstructured":"Mount Sinai. Mount Sinai study COVID-19 may be driven by pulmonary thrombi and pulmonary endothelial dysfunction. https:\/\/www.mountsinai.org\/about\/newsroom\/2020\/mount-sinai-study-finds-covid19-may-be-driven-by-pulmonary-thrombi-and-pulmonary-endothelial-dysfunction-pr (2020)."},{"key":"474_CR35","unstructured":"Cha, A. E. A mysterious blood-clotting complication is killing coronavirus patients. Washington Post https:\/\/www.washingtonpost.com\/health\/2020\/04\/22\/coronavirus-blood-clots\/ (2020)."},{"key":"474_CR36","unstructured":"Fox, M. COVID-19 causing blood clots, sudden strokes in young adults, doctors say. CTV News https:\/\/www.ctvnews.ca\/health\/coronavirus\/covid-19-causing-blood-clots-sudden-strokes-in-young-adults-doctors-say-1.4910674 (2020)."},{"key":"474_CR37","unstructured":"Cha, A. E. Young and middle-aged people, barely sick with covid-19, are dying of strokes. Washington Post https:\/\/www.washingtonpost.com\/health\/2020\/04\/24\/strokes-coronavirus-young-patients (2020)."},{"key":"474_CR38","unstructured":"Pappas, S. \u2018Silent hypoxia\u2019 may be killing COVID-19 patients. But there\u2019s hope. Live Science https:\/\/www.livescience.com\/silent-hypoxia-killing-covid-19-coronavirus-patients.html (2020)."},{"key":"474_CR39","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1089\/ham.2020.0055","volume":"21","author":"A Luks","year":"2020","unstructured":"Luks, A. et al. COVID-19 lung injury is not high altitude pulmonary edema. High Alt. Med. Biol. 21, 192\u2013193 (2020).","journal-title":"High Alt. Med. Biol."},{"key":"474_CR40","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/jth.14781","volume":"18","author":"D Lillicrap","year":"2020","unstructured":"Lillicrap, D. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. J. Thromb. Haemost. 18, 786\u2013787 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"474_CR41","unstructured":"American College of Cardiology. Feature: Thrombosis and COVID-19: FAQs for current practice. https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2020\/04\/17\/14\/42\/thrombosis-and-coronavirus-disease-2019-covid-19-faqs-for-current-practice (2020)."},{"key":"474_CR42","first-page":"19","volume":"7","author":"JC Song.","year":"2020","unstructured":"Song, J. C. et al. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19. Mil. Med. Res. 7, 19 (2020).","journal-title":"Mil. Med. Res."},{"key":"474_CR43","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/jmv.25770","volume":"92","author":"Y Gao","year":"2020","unstructured":"Gao, Y. et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J. Med. Virol. 92, 791\u2013796 (2020).","journal-title":"J. Med. Virol."},{"key":"474_CR44","doi-asserted-by":"publisher","first-page":"108427","DOI":"10.1016\/j.clim.2020.108427","volume":"215","author":"K Yuki","year":"2020","unstructured":"Yuki, K., Fujiogi, M. & Koutsogiannaki, S. COVID-19 pathophysiology: a review. Clin. Immunol. 215, 108427 (2020).","journal-title":"Clin. Immunol."},{"key":"474_CR45","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/jth.14817","volume":"18","author":"N Tang","year":"2020","unstructured":"Tang, N. et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 18, 1094\u20131099 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"474_CR46","unstructured":"American Society of Hematology. Covid-19 and coagulopathy: frequently asked questions. https:\/\/hematology.org\/covid-19\/covid-19-and-coagulopathy (2020)."},{"key":"474_CR47","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1055\/s-0040-1709650","volume":"120","author":"G Lippi","year":"2020","unstructured":"Lippi, G. & Favaloro, E. J. D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis. Thromb. Haemost. 120, 876\u2013878 (2020).","journal-title":"Thromb. Haemost"},{"key":"474_CR48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.cca.2020.03.022","volume":"506","author":"G Lippi","year":"2020","unstructured":"Lippi, G., Plebani, M. & Henry, B. M. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin. Chim. Acta. 506, 145\u2013148 (2020).","journal-title":"Clin. Chim. Acta."},{"key":"474_CR49","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1016\/j.jacc.2020.04.031","volume":"75","author":"B Bikdeli","year":"2020","unstructured":"Bikdeli, B. et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J. Am. Coll. Cardiol. 75, 2950\u20132973 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"474_CR50","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1111\/jth.14850","volume":"18","author":"M Panigada","year":"2020","unstructured":"Panigada, M. et al. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J. Thromb. Haemost. 18, 1738\u20131742 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"474_CR51","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/bjh.16749","volume":"189","author":"H Fogarty","year":"2020","unstructured":"Fogarty, H. et al. COVID-19 coagulopathy in Caucasian patients. Br. J. Haematol. 189, 1044\u20131049 (2020).","journal-title":"Br. J. Haematol"},{"key":"474_CR52","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1056\/NEJMc2013656","volume":"383","author":"L Bowles","year":"2020","unstructured":"Bowles, L. et al. Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. N. Engl. J. Med. 383, 288\u2013290 (2020).","journal-title":"N. Engl. J. Med."},{"key":"474_CR53","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.medmal.2020.03.007","volume":"50","author":"L Wang","year":"2020","unstructured":"Wang, L. C-reactive protein levels in the early stage of COVID-19. Med. Mal. Infect. 50, 332\u2013334 (2020).","journal-title":"Med. Mal. Infect."},{"key":"474_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102473","author":"Y Sun","year":"2020","unstructured":"Sun, Y. et al. Characteristics and prognostic factors of disease severity in patients with COVID-19: the Beijing experience. J. Autoimmun. https:\/\/doi.org\/10.1016\/j.jaut.2020.102473 (2020).","journal-title":"J. Autoimmun."},{"key":"474_CR55","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/jmv.25871","volume":"92","author":"C Tan","year":"2020","unstructured":"Tan, C. et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. J. Med. Virol. 92, 856\u2013862 (2020).","journal-title":"J. Med. Virol."},{"key":"474_CR56","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1161\/CIRCULATIONAHA.120.047419","volume":"141","author":"CM Campbell","year":"2020","unstructured":"Campbell, C. M. & Kahwash, R. Will complement inhibition be the new target in treating COVID-19 related systemic thrombosis? Circulation 141, 1739\u20131741 (2020).","journal-title":"Circulation"},{"key":"474_CR57","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0140-6736(20)30920-X","volume":"395","author":"H Li","year":"2020","unstructured":"Li, H. et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet 395, 1517\u20131520 (2020).","journal-title":"Lancet"},{"key":"474_CR58","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1124\/pr.115.011247","volume":"68","author":"B Mulloy","year":"2016","unstructured":"Mulloy, B., Hogwood, J., Gray, E., Lever, R. & Page, C. P. Pharmacology of heparin and related drugs. Pharmacol. Rev. 68, 76\u2013141 (2016).","journal-title":"Pharmacol. Rev."},{"key":"474_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-018-0168-2","volume":"16","author":"H Wada","year":"2018","unstructured":"Wada, H. et al. Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thrombosis J. 16, 14 (2018).","journal-title":"Thrombosis J."},{"key":"474_CR60","first-page":"414","volume":"11","author":"J Li","year":"2018","unstructured":"Li, J., Li, Y., Yang, B., Wang, H. & Li, L. Low-molecular-weight heparin treatment for acute lung injury\/acute respiratory distress syndrome: a meta-analysis of randomized controlled trials. Int. J. Clin. Exp. Med. 11, 414\u2013422 (2018).","journal-title":"Int. J. Clin. Exp. Med."},{"key":"474_CR61","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.29.971093","author":"CJ Mycroft-West","year":"2020","unstructured":"Mycroft-West, C. J. et al. The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 receptor binding domain undergoes conformational change upon heparin binding. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.02.29.971093 (2020).","journal-title":"bioRxiv"},{"key":"474_CR62","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.29.20041962","author":"T Gao","year":"2020","unstructured":"Gao, T. et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.03.29.20041962 (2020).","journal-title":"medRxiv"},{"key":"474_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100434","author":"AV Rapkiewicz","year":"2020","unstructured":"Rapkiewicz, A. V. et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series. EClinicalMedicine https:\/\/doi.org\/10.1016\/j.eclinm.2020.100434 (2020).","journal-title":"EClinicalMedicine"},{"key":"474_CR64","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S2213-2600(20)30243-5","volume":"8","author":"SE Fox","year":"2020","unstructured":"Fox, S. E. et al. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir. Med. 8, 681\u2013686 (2020).","journal-title":"Lancet Respir. Med"},{"key":"474_CR65","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1111\/jth.14844","volume":"18","author":"M Dolhnikoff","year":"2020","unstructured":"Dolhnikoff, M. et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J. Thromb. Haemost. 18, 1517\u20131519 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"474_CR66","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.kint.2020.04.003","volume":"98","author":"H Su","year":"2020","unstructured":"Su, H. et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 98, 219\u2013227 (2020).","journal-title":"Kidney Int."},{"key":"474_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2020.04.007","volume":"220","author":"C Magro","year":"2020","unstructured":"Magro, C. et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 220, 1\u201313 (2020).","journal-title":"Transl Res."},{"key":"474_CR68","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2015432","volume":"383","author":"M Ackermann","year":"2020","unstructured":"Ackermann, M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N. Engl. J. Med. 383, 120\u2013128 (2020).","journal-title":"N. Engl. J. Med."},{"key":"474_CR69","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJM199108083250604","volume":"325","author":"GA Rock","year":"1991","unstructured":"Rock, G. A. et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N. Engl. J. Med. 325, 393\u2013397 (1991).","journal-title":"N. Engl. J. Med."},{"key":"474_CR70","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3389\/fimmu.2019.00449","volume":"10","author":"S Chaturvedi","year":"2019","unstructured":"Chaturvedi, S., Brodsky, R. A. & McCrae, K. R. Complement in the pathophysiology of the antiphospholipid syndrome. Front. Immunol. 10, 449 (2019).","journal-title":"Front. Immunol."},{"key":"474_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4274\/tjh.2015.0197","volume":"33","author":"D Erkan","year":"2016","unstructured":"Erkan, D. & Salmon, J. E. The role of complement inhibition in thrombotic angiopathies and antiphospholipid syndrome. Turk. J. Haematol. 33, 1\u20137 (2016).","journal-title":"Turk. J. Haematol."},{"key":"474_CR72","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1191\/0961203303lu394oa","volume":"12","author":"RA Asherson","year":"2003","unstructured":"Asherson, R. A. et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12, 530\u2013534 (2003).","journal-title":"Lupus"},{"key":"474_CR73","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/0049-0172(94)90072-8","volume":"24","author":"G Nesher","year":"1994","unstructured":"Nesher, G., Hanna, V. E., Moore, T. L., Hersh, M. & Osborn, T. G. Thrombotic microangiographic hemolytic anemia in systemic lupus erythematosus. Semin. Arthritis Rheum. 24, 165\u2013172 (1994).","journal-title":"Semin. Arthritis Rheum."},{"key":"474_CR74","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/toxins12020067","volume":"12","author":"A Joseph","year":"2020","unstructured":"Joseph, A., Cointe, A., Kurkjian, P. M., Rafat, C. & Hertig, A. Shiga toxin-associated hemolytic uremic syndrome: a narrative review. Toxins 12, 67 (2020).","journal-title":"Toxins"},{"key":"474_CR75","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1182\/blood-2016-11-709865","volume":"129","author":"TS Jokiranta","year":"2017","unstructured":"Jokiranta, T. S. HUS and atypical HUS. Blood 129, 2847\u20132856 (2017).","journal-title":"Blood"},{"key":"474_CR76","first-page":"341342","volume":"2014","author":"G Emmi","year":"2014","unstructured":"Emmi, G., Silvestri, E., Squatrito, D. & Ciucciarelli, L. An approach to differential diagnosis of antiphospholipid antibody syndrome and related conditions. Sci. World J. 2014, 341342 (2014).","journal-title":"Sci. World J."},{"key":"474_CR77","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.trre.2018.01.001","volume":"32","author":"M Manook","year":"2018","unstructured":"Manook, M. et al. Innate networking: thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient. Transplant. Rev. 32, 119\u2013126 (2018).","journal-title":"Transplant. Rev."},{"key":"474_CR78","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jacc.2020.05.001","volume":"76","author":"I Paranjpe","year":"2020","unstructured":"Paranjpe, I. et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J. Am. Coll. Cardiol. 76, 122\u2013124 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"474_CR79","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14867","author":"I Harzallah","year":"2020","unstructured":"Harzallah, I., Debliquis, A. & Drenou, B. Lupus anticoagulant is frequent in patients with COVID-19. J. Thromb. Haemost. https:\/\/doi.org\/10.1111\/jth.14867 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"474_CR80","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2007575","volume":"382","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N. Engl. J. Med. 382, e38 (2020).","journal-title":"N. Engl. J. Med."},{"key":"474_CR81","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1053\/sarh.2002.28303","volume":"31","author":"IW Uthman","year":"2002","unstructured":"Uthman, I. W. & Gharavi, A. E. Viral infections and antiphospholipid antibodies. Semin. Arthritis Rheum. 31, 256\u2013263 (2002).","journal-title":"Semin. Arthritis Rheum."},{"key":"474_CR82","doi-asserted-by":"publisher","first-page":"176","DOI":"10.5935\/0103-507X.20140026","volume":"26","author":"J Vassalo","year":"2014","unstructured":"Vassalo, J., Spector, N., Meis, E., Soares, M. & Salluh, J. Antiphospholipid antibodies in critically ill patients. Rev. Bras. Ter. Intensiva 26, 176\u2013182 (2014).","journal-title":"Rev. Bras. Ter. Intensiva"},{"key":"474_CR83","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1182\/blood.2019003863","volume":"135","author":"S Chaturvedi","year":"2020","unstructured":"Chaturvedi, S. et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood 135, 239\u2013251 (2020).","journal-title":"Blood"},{"key":"474_CR84","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","volume":"395","author":"Z Varga","year":"2020","unstructured":"Varga, Z. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 395, 1417\u20131418 (2020).","journal-title":"Lancet"},{"key":"474_CR85","doi-asserted-by":"publisher","first-page":"102437","DOI":"10.1016\/j.bcmd.2020.102437","volume":"83","author":"A Ganji","year":"2020","unstructured":"Ganji, A., Farahani, I., Khansarinejad, B., Ghazavi, A. & Mosayebi, G. Increased expression of CD8 marker on T-cells in COVID-19 patients. Blood Cell Mol. Dis. 83, 102437 (2020).","journal-title":"Blood Cell Mol. Dis."},{"key":"474_CR86","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.thromres.2014.03.014","volume":"133","author":"F Lupu","year":"2014","unstructured":"Lupu, F., Keshari, R. S., Lambris, J. D. & Coggeshall, K. M. Crosstalk between the coagulation and complement systems in sepsis. Thromb. Res. 133, S28\u2013S31 (2014).","journal-title":"Thromb. Res."},{"key":"474_CR87","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41577-020-0320-7","volume":"20","author":"AM Risitano","year":"2020","unstructured":"Risitano, A. M. et al. Complement as a target in COVID-19? Nat. Rev. Immunol. 20, 343\u2013344 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"474_CR88","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1001\/jama.2020.4742","volume":"323","author":"AC Kalil","year":"2020","unstructured":"Kalil, A. C. Treating COVID-19\u2013off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA 323, 1897\u20131898 (2020).","journal-title":"JAMA"},{"key":"474_CR89","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta, P. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033\u20131034 (2020).","journal-title":"Lancet"},{"key":"474_CR90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436","author":"P Horby","year":"2020","unstructured":"Horby, P. et al. Dexamethasone in hospitalized patients with Covid-19 \u2014 preliminary report. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2021436 (2020).","journal-title":"N. Engl. J. Med."},{"key":"474_CR91","unstructured":"Kolata, G. Arthritis drug did not help seriously ill Covid patients, early data shows. New York Times https:\/\/www.nytimes.com\/2020\/04\/27\/health\/coronavirus-drug-sarilumab.html?referringSource=articleShare (2020),"},{"key":"474_CR92","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJMc2009567","volume":"383","author":"R Haberman","year":"2020","unstructured":"Haberman, R. et al. Covid-19 in immune-mediated inflammatory diseases \u2014 case series from New York. N. Engl. J. Med. 383, 85\u201388 (2020).","journal-title":"N. Engl. J. Med."},{"key":"474_CR93","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1111\/jth.14872","volume":"18","author":"CS Whyte","year":"2020","unstructured":"Whyte, C. S., Morrow, G. B., Mitchell, J. L., Chowdary, P. & Mutch, N. J. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. J. Thromb. Haemost. 18, 1548\u20131555 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"474_CR94","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1111\/jth.14828","volume":"18","author":"J Wang","year":"2020","unstructured":"Wang, J. et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J. Thromb. Haemost. 18, 1752\u20131755 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"474_CR95","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","volume":"382","author":"J Grein","year":"2020","unstructured":"Grein, J., Ohmagari, N., Shin, D. & Diaz, G. Compassionate use of remdesivir for patients with severe Covid-19. N. Engl. J. Med. 382, 2327\u20132336 (2020).","journal-title":"N. Engl. J. Med."},{"key":"474_CR96","unstructured":"Mcginley, L. & Rowland, C. Gilead\u2019s remdesivir improves recovery time of coronavirus patients in NIH trial. Washington Post https:\/\/www.washingtonpost.com\/business\/2020\/04\/29\/gilead-says-positive-results-coronavirus-drug-remdesivir-will-be-released-by-nih (2020)."},{"key":"474_CR97","first-page":"1049","volume":"135","author":"S Jodele","year":"2020","unstructured":"Jodele, S., Dandoy, C., Lane, A. & Laskin, B. L. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood 135, 1049\u20131057 (2020).","journal-title":"Blood"},{"key":"474_CR98","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/ckj\/sfy035","volume":"12","author":"J Menne","year":"2019","unstructured":"Menne, J. et al. Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study. Clin. Kidney J. 12, 196\u2013205 (2019).","journal-title":"Clin. Kidney J."},{"key":"474_CR99","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001000","volume":"94","author":"L Pape","year":"2015","unstructured":"Pape, L., Hartmann, H. & Bange, F. C. Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement. Medicine 94, e1000 (2015).","journal-title":"Medicine"},{"key":"474_CR100","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1093\/rheumatology\/key228","volume":"57","author":"M Buillot","year":"2018","unstructured":"Buillot, M. et al. Eculizumab for catastrophic antiphospholipid syndrome \u2014 a case report and literature review. Rheumatology 57, 2055\u20132057 (2018).","journal-title":"Rheumatology"},{"key":"474_CR101","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1172\/JCI136094","volume":"130","author":"E Gavriilake","year":"2020","unstructured":"Gavriilake, E. & Brodsky, R. A. Complementopathies and precision medicine. J. Clin. Invest. 130, 2152\u20132163 (2020).","journal-title":"J. Clin. Invest."},{"key":"474_CR102","first-page":"4040","volume":"24","author":"DF Numis","year":"2020","unstructured":"Numis, D. F. et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur. Rev. Med. Pharmacol. Sci. 24, 4040\u20134047 (2020).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"474_CR103","unstructured":"Pitts, T. C. A preliminary update to the Soliris to stop immune mediated death in Covid-19 (SOLID-C19) compassionate use study. Hudson Medical https:\/\/hudsonmedical.com\/articles\/soliris-stop-death-covid-19\/ (2020)."},{"key":"474_CR104","doi-asserted-by":"publisher","first-page":"108450","DOI":"10.1016\/j.clim.2020.108450","volume":"215","author":"S Mastaglio","year":"2020","unstructured":"Mastaglio, S. et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin. Immunol. 215, 108450 (2020).","journal-title":"Clin. Immunol."},{"key":"474_CR105","doi-asserted-by":"publisher","first-page":"ofaa102","DOI":"10.1093\/ofid\/ofaa102","volume":"7","author":"W Cao","year":"2020","unstructured":"Cao, W., Liu, X., Bai, T., Fan, H. & Hong, K. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect. Dis 7, ofaa102 (2020).","journal-title":"Open Forum Infect. Dis"},{"key":"474_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105974","author":"H Shi","year":"2020","unstructured":"Shi, H. et al. Successful treatment of plasma exchange followed by intravenous immunogloblin in a critically ill patient with 2019 novel coronavirus infection. Int. J. Antimicrob. Agents https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105974 (2020).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"474_CR107","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1097\/01.CCM.0000227659.14644.3E","volume":"34","author":"M Darmon","year":"2006","unstructured":"Darmon, M. et al. Time course of organ dysfunction in thrombotic microangiopathy patients receiving either plasma perfusion or plasma exchange. Crit. Care Med. 34, 2127\u20132133 (2006).","journal-title":"Crit. Care Med."},{"key":"474_CR108","first-page":"106","volume":"6","author":"XH Yang","year":"2020","unstructured":"Yang, X. H., Sun, R. H., Zhao, Y. & Chen, E. Z. Expert recommendations on blood purification treatment protocol for patients with severe COVID-19: recommendation and consensus. Chronic Dis. Transl Med. 6, 106\u2013114 (2020).","journal-title":"Chronic Dis. Transl Med."},{"key":"474_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.eng.2020.03.006","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. A promising anti-cytokine-storm targeted therapy for COVID-19: the artificial-liver blood-purification system. Engineering https:\/\/doi.org\/10.1016\/j.eng.2020.03.006 (2020).","journal-title":"Engineering"},{"key":"474_CR110","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1046\/j.0007-1048.2002.03353.x","volume":"116","author":"A Hodgson","year":"2002","unstructured":"Hodgson, A. et al. Plasma exchange as a source of protein C for acute onset protein C pathway failure. Br. J. Haematol. 116, 905\u2013908 (2002).","journal-title":"Br. J. Haematol."},{"key":"474_CR111","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.tmrv.2006.11.001","volume":"21","author":"T Burnouf","year":"2007","unstructured":"Burnouf, T. Modern plasma fractionation. Transfus. Med. Rev. 21, 101\u2013117 (2007).","journal-title":"Transfus. Med. Rev."},{"key":"474_CR112","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-018-2220-9","volume":"22","author":"H Knaup","year":"2018","unstructured":"Knaup, H., Stahl, K., Schmidt, B. & Idowu, T. Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. Crit. Care 22, 285 (2018).","journal-title":"Crit. Care"},{"key":"474_CR113","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.transci.2013.02.015","volume":"48","author":"H Vrielink","year":"2013","unstructured":"Vrielink, H., Karssing, W., de Korte, D. & Koopman, R. Plasmapheresis and clotting activation. Transfus. Apher. Sci. 48, 157 (2013).","journal-title":"Transfus. Apher. Sci."},{"key":"474_CR114","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2009405","volume":"383","author":"I Zagury-Orly","year":"2020","unstructured":"Zagury-Orly, I. & Schwartzstein, R. M. COVID-19 \u2014 a reminder to reason. N. Engl. J. Med. 383, e12 (2020).","journal-title":"N. Engl. J. Med"}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-0474-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-0474-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-0474-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:22:29Z","timestamp":1684606949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-020-0474-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,30]]},"references-count":114,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["474"],"URL":"https:\/\/doi.org\/10.1038\/s41584-020-0474-5","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,30]]},"assertion":[{"value":"14 July 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.T.M. declares that she has received consulting fees from Alexion Pharmaceuticals. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}